87 related articles for article (PubMed ID: 33199028)
41. Systematic review of model-based cervical screening evaluations.
Mendes D; Bains I; Vanni T; Jit M
BMC Cancer; 2015 May; 15():334. PubMed ID: 25924871
[TBL] [Abstract][Full Text] [Related]
42. A systematic review of the cost-effectiveness of interventions to increase cervical cancer screening among underserved women in Europe.
Sun L; Patel S; Fiorina C; Glass A; Rochaix L; ; Foss AM; Legood R
Eur J Health Econ; 2024 Jul; 25(5):829-844. PubMed ID: 37726429
[TBL] [Abstract][Full Text] [Related]
43. Breast and cervical cancer screening practices in nine countries of Eastern Europe and Central Asia: A population-based survey.
Znaor A; Ryzhov A; Losada ML; Carvalho A; Smelov V; Barchuk A; Valkov M; Ten E; Andreasyan D; Zhizhilashvili S; Dushimova Z; Zhuikova LD; Egorova A; Yaumenenka A; Djanklich S; Tril O; Bray F; Corbex M
J Cancer Policy; 2023 Dec; 38():100436. PubMed ID: 37544479
[TBL] [Abstract][Full Text] [Related]
44. Cervical cancer testing among women aged 30-49 years in the WHO European Region.
Williams J; Rakovac I; Victoria J; Tatarinova T; Corbex M; Barr B; Rose T; Sturua L; Obreja G; Andreasyan D; Shukurov S; Gahraman H; Mikkelsen B; Berdzuli N; Breda J
Eur J Public Health; 2021 Oct; 31(4):884-889. PubMed ID: 34491325
[TBL] [Abstract][Full Text] [Related]
45. The impact of the COVID-19 pandemic on organised cervical cancer screening: The first results of the Slovenian cervical screening programme and registry.
Ivanuš U; Jerman T; Gašper Oblak U; Meglič L; Florjančič M; Strojan Fležar M; Premru Sršen T; Smrkolj Š; Pakiž M; Primic Žakelj M; Kloboves Prevodnik V; Pogačnik A; Josipović I; Mate T; Gobec M
Lancet Reg Health Eur; 2021 Jun; 5():100101. PubMed ID: 34557821
[TBL] [Abstract][Full Text] [Related]
46. Cervical cancer in Eastern Europe: review and proceedings from the Cervical Cancer Research Conference.
Small W; Peltecu G; Puiu A; Corha A; Cocîrṭă E; Cigăran RG; Plante M; Jhingran A; Stang K; Gaffney D; Bacon M; McCormack M
Int J Gynecol Cancer; 2021 Jul; 31(7):1061-1067. PubMed ID: 33122244
[TBL] [Abstract][Full Text] [Related]
47. Cancer of the Cervix in Bulgaria: Epidemiology of a Crisis.
Yordanov A; Vasileva-Slaveva M; Galai N; Faraggi D; Kubelac MP; Tripac-Iacovleva I; Calleja N; Di Fiore R; Calleja-Agius J
Healthcare (Basel); 2023 Jan; 11(3):. PubMed ID: 36766893
[TBL] [Abstract][Full Text] [Related]
48. Correction: Chua et al. Cost-Effectiveness Analysis of HPV Extended versus Partial Genotyping for Cervical Cancer Screening in Singapore.
Chua B; Lim LM; Ng JSY; Ma Y; Wee HL; Caro JJ
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760642
[TBL] [Abstract][Full Text] [Related]
49. Introducing human papillomavirus (HPV) primary testing in the age of HPV vaccination: projected impact on colposcopy services in Wales.
Pesola F; Rebolj M; Leeson S; Dunk L; Pickford L; Gjini A; Sasieni P
BJOG; 2021 Jun; 128(7):1226-1235. PubMed ID: 33247993
[TBL] [Abstract][Full Text] [Related]
50. Estimates of the global burden of cervical cancer associated with HIV.
Stelzle D; Tanaka LF; Lee KK; Ibrahim Khalil A; Baussano I; Shah ASV; McAllister DA; Gottlieb SL; Klug SJ; Winkler AS; Bray F; Baggaley R; Clifford GM; Broutet N; Dalal S
Lancet Glob Health; 2021 Feb; 9(2):e161-e169. PubMed ID: 33212031
[TBL] [Abstract][Full Text] [Related]
51. Cervical Cancer Screening Guidelines in the Postvaccination Era: Review of the Literature.
Liverani CA; Di Giuseppe J; Giannella L; Delli Carpini G; Ciavattini A
J Oncol; 2020; 2020():8887672. PubMed ID: 33204265
[TBL] [Abstract][Full Text] [Related]
52. High frequency of HPV genotypes 59, 66, 52, 51, 39 and 56 in women from Western Mexico.
Molina-Pineda A; López-Cardona MG; Limón-Toledo LP; Cantón-Romero JC; Martínez-Silva MG; Ramos-Sánchez HV; Flores-Miramontes MG; de la Mata-González P; Jave-Suárez LF; Aguilar-Lemarroy A
BMC Infect Dis; 2020 Nov; 20(1):889. PubMed ID: 33238902
[TBL] [Abstract][Full Text] [Related]
53. Clinical Evaluation of DNA Ploidy for the Triage of HPV-Positive Chinese Women During Cervical Cancer Screening.
Cang W; Li Q; Gu L; Hong Z; Hu Y; Di W; Qiu L
Cancer Prev Res (Phila); 2021 Mar; 14(3):355-362. PubMed ID: 33229338
[TBL] [Abstract][Full Text] [Related]
54. Methodologies of Primary HPV Testing Currently Applied for Cervical Cancer Screening.
Chrysostomou AC; Kostrikis LG
Life (Basel); 2020 Nov; 10(11):. PubMed ID: 33227939
[TBL] [Abstract][Full Text] [Related]
55. Cervical Cancer Screening in Inflammatory Bowel Disease: Who Should Be Screening?
Chhaparia A; Odufalu F; Edwards M; Patel K; Christopher K; Schroeder K; Prather C; Hammami MB
Gastroenterology Res; 2020 Oct; 13(5):208-216. PubMed ID: 33224367
[TBL] [Abstract][Full Text] [Related]
56. Could HPV Testing on Self-collected Samples Be Routinely Used in an Organized Cervical Screening Program? A Modeled Analysis.
Smith MA; Hall MT; Saville M; Brotherton JML; Simms KT; Lew JB; Bateson D; Skinner SR; Kelaher M; Canfell K
Cancer Epidemiol Biomarkers Prev; 2021 Feb; 30(2):268-277. PubMed ID: 33219163
[TBL] [Abstract][Full Text] [Related]
57. Correction: Long-term protection of HPV test in women at risk of cervical cancer.
PLOS ONE Staff
PLoS One; 2020; 15(11):e0243000. PubMed ID: 33216813
[TBL] [Abstract][Full Text] [Related]
58. Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection.
Qingqing B; Jie Z; Songben Q; Juan C; Lei Z; Mu X
Microb Pathog; 2021 Mar; 152():104617. PubMed ID: 33207260
[TBL] [Abstract][Full Text] [Related]
59. Vaccination Strategies for the Control and Treatment of HPV Infection and HPV-Associated Cancer.
Farmer E; Cheng MA; Hung CF; Wu TC
Recent Results Cancer Res; 2021; 217():157-195. PubMed ID: 33200366
[TBL] [Abstract][Full Text] [Related]
60. Health economic evaluation of primary human papillomavirus screening in urban populations in China.
Keane A; Shi JF; Simms KT; Liu YJ; Lew JB; Mazariego C; Yuill S; Wu RF; Liu ZH; Zhao FH; Jeronimo J; Canfell K; Qiao YL
Cancer Epidemiol; 2021 Feb; 70():101861. PubMed ID: 33310688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
